We recognize the work of Professor Koo onthe effects of PO on early bone metabolism and note his concerns; however, when we considered other studies identified in our literature review, we do not feel the evidence against its use is conclusive and note that longer term impacts on bone were not apparent. Whilst we do not feel the evidence is sufficient torecommend against use in formula, we do strongly recommendand support the need for further research on the possible long-term health effects of PO/POL/SN-2-palmitate-based infant formulas inwell-designed RCTs.